3Frederlch R, Mcneill R, Berglind N, et al. The efficacy and safety of the dipeptidyl peptidase4 inhibitor saxagliptm intreatment- naive patients with type 2 diabetes mellitus : a randomized controlled trial[J].Diabetol Metab Syradr, 2012, 4 ( 1 ) : 36. 被引量：1
4Rosenstoc K, Jgrossj L, Saunas CA. Long-term safety and efficacy of saxagliptin after 4-year follow-up of patients with type 2 diabetes[J]. Diabetes, 2011, 60 ( Suppl 1 ) : A289-A298. 被引量：1
5Ogawq S, [shiki M, Nako K, et al. Sitagliprin, a dipeptidyl peptidases inhibitor, decreases systolic blood pressure in, Japanese hypertensive patients with type 2 diabetes[J]. Tohoku J Exp Med, 2011, 223 (2): 133-135. 被引量：1
6Koren S, Shemesh BarL, Tirosh A, et al. The effect oEsitagliptin versus glibenclamide on arterial stiffness, blood pres-sure, lipids, and inrqammation in type 2 diabetes mellitus patients/JI. Diabetes Technol Ther, 2012, 14 ( 7 ) : 561-567. 被引量：1
7MatscbakaJ, Scgiyama S, Akiyama L, et al. l)ipepti- dyl peptidases inhibitor, sitagliptin, improves endothdial dysfimction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes[J]. Circ J, 2012, 77 ( 5 ) : 1337- 1344. 被引量：1
9Glorie LL, Verhulst A, Matheeussen V, et al. DPP4 inliibition improves functional outcome after renal iacliemia-reper-fusion injury[J]. AmJ Physiol Renal Physiol, 2012, 3/)3 ( 5 ) : F681 -F688. 被引量：1
10Gongalves A, Leal E, Paiva A, et al. Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model[J]. Diabetes, Obes Metab, 2(112, 14 (5) : 454-463. 被引量：1
3Fire A, Xu S, Momgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans[J]. Nature, 1998, 391 (6 669) :806. 被引量：1
4Song E, Lee SK, Wang J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis[J]. Nat Med, 2003,9(3) :347. 被引量：1
6THORNBERRY NA, WEBER AE. Discovery of JANUVIA (Sitagliptin) , a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes [ J ]. Curr Top Med Chem, 2007, 7 (6) : 557 -568. 被引量：1
7HAVALE SH, PAL M. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes [ J ]. Bioorg Med Chem, 2009, 17 ( 5 ) : 1783 - 1802. 被引量：1
8EDMONDSON SD, MASTRACCHIO A, DUFFY JL, et al. Discovery of potent and selective orally bioavailable beta-substituted phenylalanine derived dipeptidyl peptidase IV inhibitors [ J ].Bioorg Med Chem Lett, 2005, 15(12) : 3048 -3052. 被引量：1
9DEACON CF. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes [ J ]. Curr Opin lnvestig Drugs, 2008, 9(4) : 402 -413. 被引量：1
10AUGERI DJ, ROBL JA, BETEBENNER DA, et al. Discovery and preclinical profile of Saxagliptin (BMS-477118) : a highly potent, long-acting, orally active dipeptidyl peptidase Ⅳ inhibitor for the treatment of type 2 diabetes[ J]. J Med Chem, 2005, 48(15) : 5025 -5037. 被引量：1
